Immunopharmacology Comments

Initial preclinical efficacy utilising the anti-GM-CSF strategy in a rodent RA model was reported in 2007 [4]. First in human (Phase 1b) results using namilumab were published in 2017 [1]. Namilumab has since demonstrated clinical efficacy in RA patients who have an inadequate response to methotrexate or anti-tumour necrosis factor (TNF) biologic therapy, in a Phase 2 clinical proof-of-concept study [5].

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Psoriasis	Disease Ontology: DOID:8893	Phase 2 evaluation of namilumab therapy in patients with plaque type psoriasis determined that GM-CSF blockade was not an amenable pathway for treatment of this condition.	3
Rheumatoid arthritis	Disease Ontology: DOID:7148 OMIM: 180300	Phase 2 clinical candidate for RA: namilumab has demonstrated clinical efficacy in methotexate and anti-TNF therapy-resistant RA patients	5